The neurogenesis hypothesis proposes that reduced adult hippocampal neurogenesis compromises hippocampal function in early Alzheimer’s disease (AD), causing memory impairment and cognitive decline. Augmenting neurogenesis could therefore help to slow or prevent cognitive decline in mild cognitive impairment (MCI) and mild-moderate AD. Lloyd Tran, PhD, Biomed Industries, Inc., San Jose, CA, shares evidence in support of the neurogenesis hypothesis and introduces NA-831: a small molecule synaptic AMPA receptor positive modulator under investigation for the treatment of Alzheimer’s disease (AD), based on its ability to restore adult hippocampal neurogenesis. NA-831 exhibits neurogenesis stimulating, memory enhancing, and neuroprotective properties by enhancing BDNF levels through its action on AMPA receptors. A Phase II randomized, clinical trial treated 56 patients with MCI or mild-moderate AD with NA-831 or placebo once daily for 24 weeks. In both the MCI and early AD populations, NA-831 treatment provided a significant delay in cognitive decline compared to placebo, as assessed by ADAS-Cog-13. Based on CIBIC-Plus scores (Clinician’s Interview-Based Impression of Change plus caregiver input) after the treatment period, 78% of the study participants receiving NA-831 improved. A Phase III 52-week, placebo-controlled, parallel group study has now been launched to evaluate the safety and efficacy of NA-831 in individuals with MCI due to AD or mild AD dementia. This interview took place at the Alzheimer’s Association International Conference (AAIC) 2022 in San Diego, CA.